The Wingless/Int (Wnt)/β‐catenin pathway plays an essential role in cell survival. Although post‐conditioning with 8% oxygen can alleviate transient global cerebral ischemia (tGCI)‐induced neuronal damage in hippocampal CA1 subregion in adult rats as demonstrated by our previous studies, little is understood about the role of Wnt/β‐catenin pathway in hypoxic postconditioning (HPC)‐induced neuroprotection. This study tried to investigate the involvement of Wnt/β‐catenin pathway in HPC‐induced neuroprotection against tGCI and explore the underlying molecular mechanism thereof. We observed that HPC elevated nuclear β‐catenin level as well as increased Wnt3a and decreased Dickkopf‐1 (Dkk1) expression in CA1 after tGCI. Accordingly, HPC enhanced the expression of survivin and reduced the ratio of B‐cell lymphoma/lewkmia‐2 (Bcl‐2)–associated X protein (Bax) to Bcl‐2 following reperfusion. Moreover, our study has shown that these effects of HPC were abolished by lentivirus‐mediated overexpression of Dkk1, and that the overexpression of Dkk1 completely reversed HPC‐induced neuroprotection. Furthermore, HPC suppressed the activity of glycogen synthase kinase‐3β (GSK‐3β) in CA1 after tGCI, and the inhibition of GSK‐3β activity with SB216763 increased the nuclear accumulation of β‐catenin, up‐regulated the expression of survivin, and reduced the ratio of Bax to Bcl‐2, thus preventing the delayed neuronal death after tGCI. Finally, the administration of LY294002, an inhibitor of PI3K, increased GSK‐3β activity and blocked nuclear β‐catenin accumulation, thereby decreasing survivin expression and elevating the Bax‐to‐Bcl‐2 ratio after HPC. These results suggest that activation of the Wnt/β‐catenin pathway through Dkk1 inhibition and PI3K/protein kinase B pathway–mediated GSK‐3β inactivation contributes to the neuroprotection of HPC against tGCI.—Zhan, L., Liu, D., Wen, H., Hu, J., Pang, T., Sun, W., Xu, E. Hypoxic postconditioning activates the Wnt/β‐catenin pathway and protects against transient global cerebral ischemia through Dkk1 inhibition and GSK‐3β inactivation. FASEB J. 33, 9291–9307 (2019). http://www.fasebj.org